DORMOSEDAN [detomidine hydrochloride] is a non narcotic, synthetic alpha-2 adrenoreceptor agonist equine sedative/analgesic that contains the active ingredient detomidine hydrochloride.
It is used in calming fractious horses, providing relief from abdominal pain, and facilitating bronchoscopy, bronchoalveolar lavage, nasogastric intubation, nonreproductive rectal palpations, suturing of skin lacerations, and castrations. It may also be used as a sedative and analgesic to facilitate minor surgical and diagnostic procedures in mature horses and yearlings.
**Note: This product requires a veterinarian's prescription to purchase.At checkout you will need to provide your veterinarian's FAX or email address. We will then send him or her a prescription verification that he or she will need to sign and return before we can ship you this product.
DOSAGE AND ADMINISTRATION:
For Sedation: Administer Dormosedan® IV or IM at the rates of 20 or 40 mcg detomidine hydrochloride per kg of body weight 0.2 or 0.4 mL of Dormosedan® per 100 kg or 220 lb, depending on the depth and duration of sedation required. Onset of sedative effects should be reached within 2-4 minutes after IV administration and 3-5 minutes after IM administration. Twenty mcg/kg will provide 30-90 minutes of sedation and 40 mcg/kg will provide approximately 90 minutes to 2 hours of sedation.
For Analgesia: Administer Dormosedan® IV at the rates of 20 or 40 mcg detomidine hydrochloride per kg of body weight 0.2 or 0.4 mL of Dormosedan® per 100 kg or 220 lb, depending on the depth and duration of analgesia required. Twenty mcg/kg will usually begin to take effect in 2-4 minutes and provide 30-45 minutes of analgesia. The 40 mcg/kg dose will also begin to take effect in 2-4 minutes and provide 45-75 minutes of analgesia.
For Both Sedation and Analgesia: Administer Dormosedan® IV at the rates of 20 or 40 mcg detomidine hydrochloride per kg of body weight 0.2 or 0.4 mL of Dormosedan® per 100 kg or 220 lb, depending on the depth and duration of sedation and analgesia required.
Before and after injection, the animal should be allowed to rest quietly.
Dormosedan® should not be used in horses with pre-existing AV or SA block, with severe coronary insufficiency, cerebrovascular disease, respiratory disease, or chronic renal failure. Intravenous potentiated sulfonamides should not be used in anesthetized or sedated horses as potentially fatal dysrhythmias may occur.
Information on the possible effects of detomidine hydrochloride in breeding horses is limited to uncontrolled clinical reports therefore, this drug is not recommended for use in breeding animals.
HUMAN SAFETY INFORMATION:
Dormosedan® is a potent &alpha2-agonist, and extreme caution should be exercised in its use with other sedative or analgesic drugs for they may produce additive effects.
When using any analgesic to help alleviate abdominal pain, a complete physical examination and diagnostic work-up are necessary to determine the etiology of the pain.
Food and water should be withheld until the sedative effect of Dormosedan® has worn off.
Because of continued lowering of the head during sedation, mucus discharges from the nose and, occasionally, edema of the head and face may be seen. Holding the head in a slightly elevated position generally prevents these effects.
STORAGE: Store at controlled room temperature 15°-30°C 59°-86°F in the absence of light.
HOW SUPPLIED: Dormosedan® is supplied in 5- and 20-mL multidose vials.
NADA #140-862, Approved by FDA
Manufactured by: ORION PHARMA, Orion Corporation, Espoo, Finland
Distributed by: Pfizer Animal Health, Exton, PA 19341, USA, Div. of Pfizer Inc, NY, NY 10017
Made in Finland